Clementia Pharmaceuticals Inc.がIpsen S.A.との間の提案された取引で裁判所の仮命令を得る

AsiaNet 77760（0386）

【モントリオール2019年3月8日PR Newswire＝共同通信JBN】

＊さらに他の2つの重要な株主と支持および投票の協定締結

Clementia Pharmaceuticals Inc.（NASDAQ: CMTA）は、先に発表されたIpsen S.A.との間の取り決めの計画に関し、ケベック上級裁判所から仮命令を得た、と発表した。取り決めは、Ipsen S.Aの完全子会社がClementiaの全発行済み普通株式を取引完了時に1株当たり25.00米ドルの現金前渡しで、さらに2024年12月31日またはそれ以前に米食品医薬品局（FDA）が多発性骨軟骨腫（MO）の治療のためのパロバロテンの新薬申請（NDA）を承認した時に支払われる1株当たり6.00米ドルの不確定対価受領権（CVR）の形で、将来の規制上のマイルストーンの達成に対する延べ払いで取得する、というものである。

Logo - https://mma.prnewswire.com/media/832572/Clementia_Logo.jpg

仮命令は、Clementiaがこの取引を承認するため、2019年4月9日に同社の普通株式の保有者の特別総会を招集、開催することを承認している。この取引は、総会で本人出席または委任状による株主の投票の少なくとも66 2/3%の承認、および出席本人または委任状による利害関係のない株主の過半数の承認が必要となる。

Clementiaは2019年3月8日を、総会の通知を受け取り、総会で投票する資格を得る株主を決定するための基準日として設定した。

株主が投票を行使するためのこの取引および手続きに関する詳細は、2019年3月13日ごろに郵送され、SEDARとEDGARで利用可能となる予定の総会に関する運営情報の回状、送付状、関連の委任関係資料に含まれる予定。

▽BDC CapitalとNew Enterprises Associatesが支持および投票の協定を締結

Clementiaはまた、この取引の発表に続き、それぞれ発行済み普通株式の14.0%と7.1%を保有するBDC Capital Inc.とNew Enterprise Associates 15, L.P.がいずれも支持および投票の協定を締結したと発表した。それにより、両者はこの取引を承認する特別決議に賛成の投票を行うことに同意した。以前に発表されたOrbiMed Private Investments IV, LPとClementiaの取締役および一部幹部との支持および投票の協定を考慮すると、Clementiaの発行済み普通株式の約51.7％を保有する株主がいまや同取引に賛成して議決権を行使することに同意している。

▽Clementia Pharmaceuticals Inc.について

Clementiaは、極めてまれな骨障害やその他の医療ニーズの高い疾患を抱える患者のための治療法を革新する臨床段階の企業である。Clementiaは、進行性骨化性線維異形成症（FOP）向けの新規のRARガンマ作動薬で、同社の主力製品候補であるパロバロテン（palovarotene）の承認を求めるため、2019年下半期にNDA（新薬申請）を提出する準備をしている。現在進行中の第3相MOVE試験は、FOP治療のための治験用のパロバロテンの追加投与計画を評価中である。パロバロテンはまた、多発性遺伝性外骨腫（MHE）としても知られるMOの治療のための第2相試験MO-Ped Trialに入っている。さらにClementiaは、ドライアイ疾患の潜在的治療のためのパロバロテンの点眼製剤向けの第1相試験を開始した。また、RARガンマ療法から利益を得る可能性のある他の状況も検討している。詳しい詳細は、www.clementiapharma.com を参照、またはTwitter @ClementiaPharmaで当社に連絡を。

▽問い合わせ先

Financial Community

Joseph Walewicz

EVP, Business and Corporate Development

+1 (514) 940-1080

investors@clementiapharma.com

ソース：Clementia Pharmaceuticals, Inc.

Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders

PR77760

MONTREAL, March 8, 2019 /PRNewswire=KYODO JBN/ --

Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) is pleased to announce that it

has obtained an interim order from the Quebec Superior Court in connection with

the previously announced plan of arrangement pursuant to which a wholly-owned

subsidiary of Ipsen S.A. is proposing to acquire all of the issued and outstanding

common shares of Clementia for US$25.00 per share in cash upfront on completion

of the transaction plus a deferred payment on the achievement of a future regulatory

milestone in the form of a contingent value right (CVR) of US$6.00 per share payable

upon the U.S. Food and Drug Administration (FDA) acceptance of the New Drug

Application (NDA) filing for palovarotene for the treatment of multiple

osteochondromas (MO) on or prior to December 31, 2024.

Logo - https://mma.prnewswire.com/media/832572/Clementia_Logo.jpg

The interim order authorizes Clementia to call and hold on April 9, 2019 a

special meeting of the holders of its common shares to approve the transaction.

The transaction will require the approval of at least 66 2/3% of the votes cast

by shareholders present in person or represented by proxy at the meeting as

well as the approval of a majority of the votes cast by the Clementia's disinterested

shareholders present in person or represented by proxy at the meeting.

Clementia has set March 8, 2019 as the record date for the determination of the

shareholders entitled to receive notice of and to vote at the meeting.

Further details regarding the transaction and the procedure for shareholders to

vote their common shares will be included in the management information

circular, the letter of transmittal and the related proxy materials in respect

of the meeting, which are expected to be mailed and made available on SEDAR and

EDGAR on or about March 13, 2019.

BDC Capital and New Enterprises Associates Enter into Support and Voting

Agreements

Clementia also announces that following the announcement of the transaction,

BDC Capital Inc. and New Enterprise Associates 15, L.P., who respectively own

approximately 14.0% and 7.1% of the issued and outstanding common shares,

have each entered into a support and voting agreement pursuant to which they

have agreed to vote their common shares in favour of the special resolution

approving the transaction. Considering the previously announced support and

voting agreements entered into by OrbiMed Private Investments IV, LP and the

directors and certain officers of Clementia, shareholders owning approximately

51.7% of Clementia's issued and outstanding common shares have now agreed to

vote their common shares in favour of the transaction.

About Clementia Pharmaceuticals Inc.

Clementia is a clinical-stage company innovating treatments for people with

ultra-rare bone disorders and other diseases with high medical need. Clementia

is preparing to submit an NDA in the second half of 2019 to seek approval of

its lead product candidate, palovarotene, a novel RAR gamma agonist, for

fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is

evaluating an additional dosing regimen of investigational palovarotene for the

treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial,

for the treatment of MO, also known as multiple hereditary exostoses (MHE).

In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation

of palovarotene for the potential treatment of dry eye disease and is also

investigating other conditions that may benefit from RAR gamma therapy.

For more information, please visit www.clementiapharma.com and connect with us

on Twitter @ClementiaPharma.

Forward Looking Statements

This press release may include "forward-looking statements" within the meaning

of the applicable securities laws, including with respect to the timing and

completion of the arrangement, the proposed timing of filings and submissions

with the FDA for palovarotene and the impact of the proposed transaction on

Clementia and the operations of Clementia post-transaction. Each forward-looking

statement contained in this press release is subject to known and unknown risks

and uncertainties and other unknown factors that could cause actual results to differ

materially from historical results and those expressed or implied by such statement.

In addition to statements which explicitly describe such risks and uncertainties,

readers are urged to consider statements labeled with the terms "believes", "belief,"

"expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking.

Applicable risks and uncertainties include, among others, the risk that a condition to

closing of the arrangement may not be satisfied, the risk that any required shareholder,

court or applicable regulatory approvals for the arrangement may not be obtained or

be obtained subject to conditions that are not anticipated, the outcome of the FDA

approval of palovarotene product candidate for the treatment of MO,

Clementia's ability to successfully complete in a timely manner the studies required

to be completed in order to submit the NDA, Clementia's ability to generate revenue

and become profitable, the risks related to its heavy reliance on palovarotene,

its only current product candidate, the risks associated with the development of

palovarotene and any future product candidate, including the demonstration of

efficacy and safety, Clementia's dependence on licensed intellectual property,

including the ability to source and maintain licenses from third-party owners;

as well as the risks identified in Clementia's public filings with the SEC and

the Quebec Autorite des Marches Financiers. Clementia cautions investors not to rely

on the forward-looking statements contained in this press release when making an

investment decision in their securities. Investors are encouraged to read

Clementia's filings with the SEC or on SEDAR, available at www.sec.gov or

www.sedar.com, for a discussion of these and other risks and uncertainties. The

forward-looking statements in this press release speak only as of the date of

this press release, and Clementia undertakes no obligation to update or revise

any of these statements, whether as a result of new information, future events

or otherwise, except as required by law.

For further information:

Financial Community: Joseph Walewicz, EVP, Business and Corporate Development,

+1 (514) 940-1080, investors@clementiapharma.com

SOURCE  Clementia Pharmaceuticals, Inc.